SG Americas Securities LLC Has $104,000 Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT)

SG Americas Securities LLC lifted its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT) by 103.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 81,669 shares of the company’s stock after purchasing an additional 41,573 shares during the quarter. SG Americas Securities LLC owned 0.10% of Editas Medicine worth $104,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Jacobs Levy Equity Management Inc. grew its holdings in shares of Editas Medicine by 133.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 529,834 shares of the company’s stock worth $1,807,000 after purchasing an additional 302,652 shares in the last quarter. Barclays PLC grew its holdings in shares of Editas Medicine by 46.9% during the 3rd quarter. Barclays PLC now owns 178,507 shares of the company’s stock worth $607,000 after purchasing an additional 56,986 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Editas Medicine by 37.3% in the third quarter. BNP Paribas Financial Markets now owns 54,787 shares of the company’s stock valued at $187,000 after buying an additional 14,888 shares in the last quarter. FMR LLC boosted its stake in Editas Medicine by 110.7% in the third quarter. FMR LLC now owns 203,087 shares of the company’s stock valued at $693,000 after buying an additional 106,684 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Editas Medicine in the third quarter valued at about $240,000. 71.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Evercore ISI reduced their price objective on Editas Medicine from $7.00 to $5.00 and set an “outperform” rating on the stock in a research note on Monday, December 16th. Robert W. Baird lowered their price objective on Editas Medicine from $10.00 to $8.00 and set an “outperform” rating for the company in a research report on Friday, December 13th. Wells Fargo & Company downgraded Editas Medicine from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $7.00 to $4.00 in a research report on Wednesday, December 11th. Bank of America downgraded Editas Medicine from a “buy” rating to an “underperform” rating and lowered their target price for the stock from $13.00 to $1.00 in a report on Monday, November 25th. Finally, Raymond James downgraded Editas Medicine from an “outperform” rating to a “market perform” rating in a report on Monday, November 4th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $7.00.

Editas Medicine Stock Up 0.8 %

Shares of NASDAQ:EDIT opened at $1.19 on Thursday. The stock has a market cap of $98.23 million, a price-to-earnings ratio of -0.46 and a beta of 1.94. Editas Medicine, Inc. has a 12-month low of $1.12 and a 12-month high of $11.58. The business’s 50 day moving average is $1.41 and its 200 day moving average is $2.74.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.